Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data on June 5. The update will include data on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week treatment data on the efficacy and safety of tobevibart and elebsiran for the participants that were previously reported on at the 2023 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.

The SOLSTICE trial (NCT05461170) is evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta. New data will be presented from the cohorts evaluating the de novo combination of tobevibart and elebsiran dosed every four weeks and tobevibart monotherapy every two weeks. Additional 24-week data from these cohorts are expected in the fourth quarter of 2024.

About Tobevibart (VIR-3434)

Tobevibart is an investigational subcutaneously administered antibody designed to block entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against hepatitis B virus and hepatitis delta virus, as well as to have an extended half-life. Tobevibart was identified using Vir’s proprietary monoclonal antibody discovery platform.

About Elebsiran (VIR-2218)

Elebsiran is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an effective immune response and have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially could result in an increased therapeutic index. Elebsiran is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.